Brokerages are staying positive on a select group of Indian stocks for 2026, with Dr Lal PathLabs and IDFC First Bank featuring in a list of five names seen as potential long-term return candidates. The broader view remains constructive across healthcare, banking, defence, pharmaceuticals and specialty chemicals, where analysts see improving earnings prospects and resilient business fundamentals.
The theme behind these recommendations is selective stock picking rather than a blanket sector call. Firms with stronger balance sheets, clearer growth visibility and better operating performance appear to be attracting the most favourable outlooks. Based on the headline list, the expected return potential on these ideas ranges from about 10% to 30% over the longer term.
One of the specific calls highlighted is Granules India. Emkay Global has kept its Buy rating on the pharmaceutical company and assigned a target price of Rs 950, compared with a last traded price of Rs 833. That implies a possible upside of roughly 14%, making it one of the monitored ideas within the broader set of recommended long-term stocks.
Overall, the brokerage stance suggests confidence in sectors linked to steady demand and earnings recovery. While the detailed rationale for each of the five stocks is not fully available in the trimmed report, the published summary points to a mix of healthcare, banking, defence, pharma and specialty chemicals names as areas where analysts still see value for 2026 investors.
